Navigation Links
Big Pharma and Universities Increasingly Work to Advance Life Science Knowledge by Forming Strategic Partnerships, Public-Private Partnerships, and Open Innovation Programs: Pharmaceutical Research Collaborations Summit
Date:6/15/2012

NEW YORK, June 15, 2012 /PRNewswire/ -- ExL Pharma will host the 2nd Pharmaceutical Research Collaborations Summit August 14-15 at the Hyatt Harborside in Boston.

One of the critical questions facing the pharmaceutical industry today is where will future R&D dollars come from. The patent cliff and other forces are making it difficult for large pharmaceutical companies to maintain large-scale internal research departments.  As a result, pharmaceutical companies frequently look outside of their company to benefit from discoveries that may be further along the development pipeline, reducing the financial risk of bringing them further.

The two-day program focuses on various strategies pharmaceutical companies take to benefit from outside research. Sessions will highlight case studies on partnerships between large pharmaceutical and biotech companies, universities, small biotechs, and virtual pharma companies.  Panelists will discuss the different goals of the different institutions, venture capital opportunities, and intellectual property considerations.  Attendees will hear presentations on open innovation case studies, regulatory issues, and the finer points of alliance management.

The diverse speaker staff draws from some of the leading life science research institutions and companies, including MIT, Abbott Ventures, Boston University, Biogen Idec, Tufts, Merck, Millennium, Novartis, Yale, Pfizer, Sanofi, and more. These different points of view will shed light on the dynamics that promise to drive scientific research in coming years.

To find out more information regarding attending the 2nd Pharmaceutical Research Collaborations Summit, please contact Shari Gelfand on sgelfand@exlpharma.com or visit 2nd Pharmaceutical Research Collaborations Summit.

About ExL Pharma

ExL Pharma, a division of ExL Events, Inc., is the industry leader in developing innovative, educational conferences that serve the pharmaceutical and allied healthcare communities in the United States, Europe, Latin America and various markets. Behind our diverse pharmaceutical event portfolio, ExL's experienced team conducts extensive market research and targeted outreach. The results translate into innovative, high-quality events designed to exceed the dynamic informational and networking needs of specific audiences and working groups.

Press Contact:
Shari Gelfand
(917) 258-5145
sgelfand@exlpharma.com


'/>"/>
SOURCE ExL Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
2. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
3. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
4. Genesis Biopharma Mentioned Favorably in BioMedReports Article
5. Genesis Biopharma Issues Letter To Shareholders
6. New Competitive Arena Emerges for Pharmaceutical Companies in Healthcares Changing Payment Landscape, Finds PwC Health Research Institute Study
7. Questcor Pharmaceuticals Expands Repurchase Program
8. PharmAthene Reports First Quarter 2012 Financial Results
9. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
10. PDL BioPharma to Present at Upcoming Conferences
11. China Pharma Holdings, Inc. to Report First Quarter of Fiscal Year 2012 Financial Results on May 15, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
Breaking Biology News(10 mins):